In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Myriad gets rights to Encore Pharmaceuticals' MPC-7869

Executive Summary

Myriad Genetics (pharmaceutical and diagnostic products) has received exclusive worldwide development, manufacturing, and marketing rights to Encore Pharmaceuticals' (cardiovascular and antineoplastic drugs) MPC-7869 (formerly E-7869) for prostate, colon, and other cancers. Phase IIa clinical trials have just been completed in prostate cancer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies